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CX-5461 is a DNA G-quadruplex stabilizer with
selective lethality in BRCA1/2 deﬁcient tumours
Hong Xu1, Marco Di Antonio2,3, Steven McKinney1, Veena Mathew4, Brandon Ho5, Nigel J. O’Neil6,
Nancy Dos Santos7, Jennifer Silvester8, Vivien Wei1, Jessica Garcia1, Farhia Kabeer1, Daniel Lai1, Priscilla Soriano1,
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G-quadruplex DNAs form four-stranded helical structures and are proposed to play key roles
in different cellular processes. Targeting G-quadruplex DNAs for cancer treatment is a very
promising prospect. Here, we show that CX-5461 is a G-quadruplex stabilizer, with speciﬁc
toxicity against BRCA deﬁciencies in cancer cells and polyclonal patient-derived xenograft
models, including tumours resistant to PARP inhibition. Exposure to CX-5461, and its related
drug CX-3543, blocks replication forks and induces ssDNA gaps or breaks. The BRCA and
NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage
and failure to do so leads to lethality. These data strengthen the concept of G4 targeting as a
therapeutic approach, speciﬁcally for targeting HR and NHEJ deﬁcient cancers and other
tumours deﬁcient for DNA damage repair. CX-5461 is now in advanced phase I clinical
trial for patients with BRCA1/2 deﬁcient tumours (Canadian trial, NCT02719977, opened
May 2016).
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nherited BRCA2 mutations predispose carriers to early onset
breast, ovarian and other cancers1,2. As an important tumour
suppressor, the key role of BRCA2 is in homologous
recombination (HR)-mediated DNA damage repair by
promoting the formation of RAD51 ﬁlaments at DNA breaks3.
When BRCA2 is deﬁcient, HR repair efﬁciency is greatly
compromised, leading to an increased error-prone DNA repair
and ultimately, genomic instability. The BRCA2/RAD51 complex
is also involved in many other aspects of genome instability, such
as stalled DNA replication fork stabilization4, R-loop resolution
and repairing G-quadruplex (G4) associated DNA damage5,6.
G4 structures can potentially form at over 700,000 sequences in
the human genome7,8, and 10,000 of them have been identiﬁed
from ChIP-seq using an antibody that recognises G4 structures9.
G4 structures increase the tendency for DNA damage to occur, by
impeding DNA polymerase and DNA damage repair processes10.
The importance of the HR pathway in repairing G4-induced
DNA damage has been demonstrated in different organisms11,12.
BRCA2-deﬁcient cells display higher sensitivity to tool
compounds such as pyridostatin (PDS)13 and RHS4 (ref. 6),
which are both G4 stabilizers, but not medicinal compounds and
are structurally unrelated to the ﬂuoroquinolone derived CX
series compounds.
As a general phenomenon in cancer, there is an increased
requirement for rDNA transcription to meet the greater protein
synthesis demand in cancer cells14. Some new inhibitors of rDNA
transcription have been synthesized in recent years, such as
CX-5461, CX-3543 and BMH-21 (refs 15–17). CX-3543 binds to
G4 sequences and disrupts the interaction of rDNA G4 structures
with nucleolin, thereby inhibiting Pol I transcription and
inducing apoptotic death in cancer cells16. BMH-21 acts by its
interaction with the DNA backbone in GC-rich DNA sequences,
particularly at rDNA loci, thus inhibiting Pol I transcription and
also promoting degradation of Pol I catalytic subunit RPA194
(ref. 18). CX-5461 is an rDNA transcription inhibitor currently in
phase I trials for haematologic malignancies. CX-5461 reduces
the binding afﬁnity of the SL1 pre-initiation complex and
RNA polymerase I complex to rDNA promoters and conveys
p53-dependent anti-tumorigenic activity in hematopoietic
malignancies15,17. Recently, more targets of CX-5461 have
been discovered, such as the activation of ATM/ATR19 and
rapamycin-associated signalling pathway20.
In the present study, we have uncovered a new and
unanticipated mechanism of CX-5461 activity in HR and
non-homologous end joining (NHEJ) deﬁcient cancer cells. We
show that both CX-5461 and the related compound CX-3543
induce DNA damage and are dependent on BRCA1/2-mediated
HR and DNA-PK-mediated NHEJ pathway for damage repair.
We also discover that CX-5461 (and CX-3543) bind and stabilize
G4 DNA structures in vitro, impede the progression of DNA
replication complexes and result in increased in vivo G4
structures. The pattern of activity in polyclonal patient-derived
xenografts (PDX) mirrors that seen in vitro with isogenic cell line
pairs, namely sensitivity in BRCA deﬁcient PDX models, in the
context of pre-treatment with taxane and other standard of care
agents. In some cases, superior activity to PARP inhibition is
observed. Our data suggest that the CX drugs, and possibly other
G4 stabilizers have the potential to treat cancers deﬁcient for
BRCA1, BRCA2, NHEJ pathway members and some other genes
involved in DNA damage repair and DNA replication. Since
CX5461 is an advanced phase I medicinal compound, these
observations have immediate translational signiﬁcance.
Results
CX-5461 selectively inhibits cancer cells deﬁcient for BRCA1/2.
To identify potential novel drugs for cancers with BRCA2
mutations, we tested a total of 17 commercially available inhibi-
tors (Supplementary Table 1) by clonogenic assays in
isogenic BRCA2 knockout and wild type (WT) HCT116 cell
line pairs published by us21. This clonogenic screen identiﬁed
CX-5461, a previously described RNA pol I inhibitor15,17 to be
highly toxic to BRCA2 knockout HCT116 cells as compared
with isogenic BRCA2 WT cells (Fig. 1a). We extended the
quantiﬁcation of this observation by using a WST-1 metabolic/
cell viability assay. As with the clonogenic assay, this revealed a
9.0-fold (95% conﬁdence interval (CI), 5.1–16.2) lower IC50 in
BRCA2 deﬁcient HCT116 cells than in BRCA2 proﬁcient cells
(Fig. 1b, Supplementary Fig. 1a). Importantly, we observed in this
experiment and those described below, that BRCA2 heterozygous
cells displayed similar sensitivity to CX-5461 as BRCA2 proﬁcient
wild-type cells (Fig. 1b,d). We also assessed cell death speciﬁcally
through ﬂuorescence-activated cell sorting (FACS) by annexin V
and PI double staining. As shown in Fig. 1c and Supplementary
Table 5, CX-5461 induced more apoptotic cell death in BRCA2
knockout cells relative to WT. However, BRCA2þ /þ and
BRCA2 / isogenic cells in HCT116 appeared equally
sensitive to actinomycin (an inhibitor for both RNA polymerase
I and II) and cycloheximide (an inhibitor for protein translation
elongation) (Supplementary Fig. 1b,c). Together, these data
indicate that BRCA2 deﬁcient cells are not generally sensitive
to transcription and translation inhibition, but show speciﬁc
sensitivity to CX-5461.
We next sought to determine whether the selective killing effect
of CX-5461 in BRCA2 deﬁcient cells could be observed in other
cell lines and species backgrounds. We measured CX5461 drug
sensitivity in isogenic BRCA2 / and WT colorectal cancer
DLD1 cells; BRCA2 deﬁcient ovarian cancer cell line PEO1 vs the
BRCA2 proﬁcient C4-2 (ref. 22); and BRCA2 proﬁcient and
knockout breast tumour cells derived from p53 knockout mouse
(BRCA2 / ; p53 / (KB2P 1.21) vs BRCA2þ /þ ; p53 /
(KP6.3) cells)23. In all these cell line pairs, BRCA2-deﬁcient cells
were more sensitive to CX-5461 than BRCA2 proﬁcient cells
(Fig. 1d,e, Supplementary Figs 1d and 2a–c). When BRCA2 was
transiently knocked down in U2OS, increased sensitivity to
CX-5416 was also observed (Supplementary Fig. 2d).
In p53 / HCT116 cells, drug sensitivity to CX-5461
increased signiﬁcantly (F-test P¼ 0.01) after BRCA2 knockdown
(Fig. 1f). This supports the notion that the selective toxicity of
CX-5461 to BRCA2 deﬁcient cells is not dependent on p53 in
epithelial cells17. BRCA1 is another critical component of the
HR repair pathway and is also involved in replication fork
stabilization24,25. Encouragingly, increased drug sensitivity to
CX-5461 was observed when BRCA1 was knocked down in
p53þ /þ and p53 / HCT116 (Supplementary Fig. 2e), further
supporting that synthetic lethality with CX-5461 does not
require wild type p53. We also note (below) that CX-5461
sensitivity is seen in polyclonal p53 deﬁcient PDX tumours
(model CFIB-70620).
BRCA2 is not synthetic lethal with rDNA transcription inhibition.
We set out to address the possible molecular mechanism by
which CX-5461 causes synthetic lethality in BRCA2 deﬁcient
cells. Since CX-5461 has documented RNA pol I inhibition
activity, we investigated this notion ﬁrst, by examining the effects
of a related compound CX-3543 (quarﬂoxin) and an unrelated
small molecule BMH-21. Both of these molecules are reported to
suppress rDNA transcription, but by different mechanisms16,18.
In DLD1 cells, BRCA2 / cells were highly sensitive to CX-3543
compared with isogenic BRCA2þ /þ cells (Supplementary
Fig. 3d). In contrast, BRCA2 / cells were not more sensitive
to BMH-21 than isogenic WT cells in either HCT116 or DLD1
(Fig. 1h, Supplementary Fig. 3a,b).
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Since BRCA2 deﬁcient cells showed differential response to
the three rRNA transcription inhibitors, we sought to verify
the activity against rDNA transcription in the cells used. We
measured the amount of 45S pre-rRNA as a readout for rDNA
transcription by qRT-PCR, as previously described16, at 2 and
24 h after treatment. In these experiments, BMH-21 was at least
as potent an rDNA transcription inhibitor as CX-5461 and
CX-3543 (Fig. 1g, Supplementary Fig. 3g), consistent with
published activity18. However, the same or greater level
(median 1–2 fold for CX-5461, CX-3543 at 10 6M vs median
WT
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16-fold for BMH-21 at 10 6M, Fig. 1g, Supplementary Fig. 3g)
of rDNA transcription inhibition by BMH-21 did not result in
selective toxicity against BRCA2 / cells, in contrast with
CX-5461 and CX-3543. We also noted that the IC50 of CX-5461
in the cell lines used is 4.80 10 9M (Fig. 1b, Supplementary
Fig. 1a) for BRCA2 knockout HCT116 cells, a concentration at
which rDNA transcription inhibition was not observed. We thus
concluded that rDNA transcription inhibition alone is not
required for the selective toxicity of CX-5461 and CX-3543
against BRCA2 deﬁcient cells.
We also compromised rDNA transcription with RNAi against
POLR1B, an essential component in the RNA pol I complex.
Upon POLR1B knockdown, rDNA transcription was signiﬁcantly
reduced (Supplementary Fig. 3c), and cell viability also greatly
decreased by single RNA pol I knockdown, making measurement
of synergy with BRCA2 (double knockdown) difﬁcult. In U2OS
cells, POLR1B and BRCA2 double knockdown reduced cell
viability at a level comparable with single POLR1B knockdown
(Supplementary Fig. 3f), with non-statistical difference seen,
consistent with the absence of a synthetic genetic effect in U2OS.
In HCT116, slightly more cell death was observed in
double knockdown cells compared with single knockdown cells
(omnibus test Po0.0001) (Supplementary Fig. 3e), however the
single RNA pol I knockdown induces many fold greater cell death
than the knockdown of BRCA2, precluding accurate assessment
of synthetic lethality. Taken together with the results of BMH-21,
the data disfavour rDNA transcription inhibition as an important
mechanism of CX-5461 toxicity in BRCA2 deﬁcient cells.
When drug sensitivity of CX-5461, CX-3543, and BMH-21 was
compared across 50 breast cancer cell lines, the response
signature of BMH-21 was different from CX-5461 and CX3543
(Fig. 7d, Supplementary Table 4). BMH-21 is only moderately
cytotoxic to a few breast cancer cell lines, while CX-3543 has
response pattern very similar to CX-5461 and is clustered
together with CX-5461 (Fig. 7d), consistent with a similar mode
of action between CX-3543 and CX-5461, but distinct in the case
of BMH-21.
CX-5461 and CX-3543 induce DNA damage in tumour cells.
As the major cellular functions of BRCA2 are DNA damage
repair and replication fork stabilization, we investigated DNA
damage response upon exposure to CX-5461, CX-3543 and
BMH-21. Strikingly, g-H2AX and 53BP1 DNA damage foci were
robustly induced by CX-5461 and CX-3543 in both HCT116 and
U2OS cells when the drug concentration was higher than 10 8M
(Fig. 2a–c). In marked contrast, no g-H2AX or 53BP1 focus
formation was visible with 10 8M and 10 7M BMH-21,
although 10 6M BMH-21 induced a statistically signiﬁcant level
of damage foci that was slightly higher (Fig. 2b,c). Consistent with
the result of DNA damage protein focus formation, increased
phosphorylation of H2AX was observed after CX-5461 and
CX-3543 treatment by Western blotting analysis (Fig. 4a,
Supplementary Fig. 4a). As shown above, BMH-21 inhibited
rDNA transcription more potently than CX-5461 and CX-3543
(Fig. 1g). However, BMH-21 did not appear to be associated with
the same degree of DNA damage and cell death as CX-5461 and
CX-3543 at the same concentration. Moreover, reduction of
rDNA transcription by siRNA for POLR1B did not result in more
g-H2AX and 53BP1 foci formation (Supplementary Fig. 4b).
Collectively, these data strongly suggest that CX-5461 and
CX-3543 are potent DNA damage inducers, and this mechanism
is independent of rDNA transcription inhibition in the cell types
examined. We also excluded the possibility that the DNA damage
phenotype was an indirect effect of nucleolus disruption, because
DNA damage foci were observed when the concentration of
CX-5461 was not able to disrupt nucleolus (Supplementary
Fig. 4e).
In order to better quantify the amount and type of DNA
damage, a comet tail forming assay26 was applied to short
exposure CX-5461 treated cells. After 30min of drug exposure,
statistically increased comet tail-moments were observed under
alkaline conditions when the concentration of CX-5461 was
higher than 10 7M (Po10 15, w2 test for all drug
concentrations tested) (Fig. 2d,e). Under neutral comet assay
conditions, which are more speciﬁc for DSBs, we discovered a
small but statistically signiﬁcant increase in tail moments
(Po10 6, w2 test for all drug concentrations, Fig. 2d). Thus,
upon short exposure (30min) to CX-5461, the initial forms of
DNA damage occurring are mainly SSBs or gaps and a lower
abundance of DSBs.
Remarkably, CX-5461 (Supplementary Fig. 4d) also induced
DNA damage foci in yeast and selectively killed yeast lacking
RAD52 (Supplementary Fig. 4h), a functional homologue of
BRCA2, further supporting DNA as the drug target of CX-5461
and CX-3543.
CX-5461 and CX-3543 induced DNA damage is replication-
dependent. To further investigate the mechanism of CX-5461
and CX-3543 induced DNA damage, cell cycle analysis was
performed on drug treated HCT116 cells by FACS with EdU and
PI staining. Shortly after 10 6M CX-5461 treatment (2 h),
active replication shown by EdU staining decreased signiﬁcantly
(7.1% decrease; 95% CI, 2.6–11.5%) in BRCA2þ /þ cells (Fig. 3a).
At a later time point (24 h after), CX-5461 induced a prominent
Figure 1 | BRCA2 deﬁcient cells are highly sensitive to CX-5461 in different human and murine cell types. (a) The colony formation capacity of
BRCA2 / HCT116 cells was greatly reduced by treatment with CX-5461. Experiments were repeated twice with similar results. Scale bar, 1 cm. (b) The
hypersensitivity of BRCA2 / cells to CX-5461 in HCT116 validated by WST-1 assay. Representative experiment #3 (see Supplementary Fig. 1a for full
experimental panels, n¼ 9) is displayed as individual data points and as ﬁtted sigmoid dose response curves (green for BRCA2 deﬁcient and red for BRCA2
wild type). Dashed vertical lines are the IC50. (c) CX-5461 induced more apoptosis in BRCA2 / cells as indicated by FACS analysis. A representative
result is shown on the left panel and the right panel shows mean apoptotic fraction with 95% CI of cells in early apoptosis under different drug
concentrations. ***Po0.0001, t-test; n¼ 3, 2 or more replicates per condition. See Supplementary Table 5 for more statistical analyses. (d) BRCA2 / in
DLD1 isogenic cell line pairs displayed hypersensitivity to CX-5461 by WST-1 assay. Representative experiment #3 is shown (see Supplementary Fig. 2a for
full experimental panels; n¼4). Green ﬁtted sigmoid curves are for BRCA2 homozygous (HOM) and red for BRCA2 wild type and heterozygous (HET).
(e) BRCA2 deﬁcient ovarian cancer PEO1 cells exhibited increased sensitivity to CX-5461 relative to BRCA2 proﬁcient C4-2 cells by WST-1 assay.
A representative experiment #1 is displayed (see Supplementary Fig. 2b for full experimental panels, n¼ 3). (f) RNAi knockdown of BRCA2 increased
sensitivity to CX-5461 in p53 / HCT116 cells by WST-1 assay (4 days in drug). The results of all three experiments are summarized by the green (BRCA2
knockdown) and red (non-targeting control) super-smoother ﬁt lines. (g) 45S pre-rRNA level measured by RT-PCR after CX-5461, CX-3543 and BMH-21
treatment in WT and BRCA2 / HCT116 cells. Drug incubation time was 24h. Fold change estimates and unadjusted 95% CIs of 45s pre-rRNA levels
under drug treatment condition versus vehicle control are shown. P values (by F-test) are shown in Supplementary Table 7. (h) BRCA2 knockout cells are
not more sensitive to BMH-21 in HCT116 through WST-1 assay. One representative experimental result is shown (more replicates are shown in
Supplementary Fig. 3a).
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Figure 2 | DNA damage is induced in cells with CX-5461 and CX-3543 treatment. (a) The formation of g-H2AX, 53BP1, RPA and RAD51 foci was
monitored upon CX-5461, CX-3543 and BMH-21 treatment at 10 7M in U2OS cells. Drug treatment time is 24 h for all drugs. Scale bar, 10mM.
(b) Beanplots of U2OS cells showing ﬁve or more g-H2AX foci for the indicated drug treatment condition after 24 h. **Po0.01 (one tailed randomization
tests adjusted for multiple comparisons relative to vehicle control); n¼ 2 experiments, (35–150 cells were counted each time per each condition). DMSO
was the vehicle control solvent for CX-3543 and NaH2PO4 was the vehicle control solvent for BMH-21 and CX-5461. (c) Beanplots of HCT116 cells showing
three or more 53BP1 foci for the indicated drug treatment conditions after 24 h. **Po0.01, ***Po0.0001 (one-tailed randomization tests adjusted for
multiple comparisons relative to vehicle control); n¼ 3 experiments; 4100 cells per replicate condition. (d) Quantiﬁcation of alkaline comet and neutral
comet assay result upon CX-5461 treatment (30min) in HCT116. Tail moments were determined as described in Methods; (n¼ 3 experiments, 100 cells
were counted in each replica), mean and 95% CI are shown. Right panels show pair-wise comparison of condition contrasts and 95% CIs of tail moment
difference. (e) Representative images of alkaline comet assay of cells treated with CX-5461 (10 6M, 30min) and no drug control. Scale bar, 20mM.
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G2 arrest (41% increase; 95% CI, 37–45%), blocking cells before
mitosis (Supplementary Fig. 5b). In HCT116 BRCA2 / cells,
the decrease of S-phase population was more dramatic (10.2%
decrease; 95% CI, 5.6–14.9%, 2 vs 0 h, Fig. 3a, Supplementary
Fig. 5a, Supplementary Table 6).
To determine whether the DNA damage was occurring in
S-phase, we blocked DNA replication with aphidicolin (APH),
a DNA polymerase inhibitor. Strikingly, for EdU positive S phase
cells, APH pre-treatment remarkably reduced the percentage of
cells with DNA damage foci relative to CX-5461 only treatment
in both WT (decreased 48.6%; 95% CI, 44.2–51.2%) and
BRCA2 / cells (decreased 68.5%; 95% CI, 57.1–75.2%)
(Fig. 3b,c). But for EdU negative cells, APH treatment showed
no effect. The predominance of DNA damage foci in S-phase
population and its dependence on DNA replication were also
observed with CX-3543 treatment (Supplementary Fig. 5c,d).
Likely, CX-5461 and CX-3543 bind to DNA and impede DNA
replication forks, with the consequence that non-resolved stalled
forks give rise early on to ssDNA gaps and breaks. In line with
this model, RPA complex, which speciﬁcally accumulates at
ssDNA tracts, formed foci after CX-5461 and CX-3543 treatment
(Fig. 2a, Supplementary Fig. 4f), and the ATR–CHK1 pathway
was activated as revealed by increased phosphorylation of CHK1
and CHK2 with CX-5461 treatment (Supplementary Fig. 4c).
Collectively, these data suggest that CX-5461 and CX-3543
induce replication-dependent DNA damage.
To better deﬁne the nature of this replication defect caused by
CX-5461/CX-3543, DNA ﬁbre analysis was utilized to monitor
DNA replication at a single molecule level. In this procedure,
nascent replication tracks were labelled before (green CIdU
labelling) and after (red IdU labelling) CX-5461 treatment
to evaluate its immediate effect (30min) on replication.
CX-5461 substantially shortened replication track length in both
BRCA2þ /þ and BRCA2 / HCT116 cells, and this effect was
more prominent in BRCA2 / cells (Fig. 3d). Signiﬁcant fork
rate reduction was observed in the presence of CX-5461 at a
concentration 10 times lower in BRCA2 / cells than in
BRCA2þ /þ cells. Thus, CX-5461 blocks replication fork
progression and BRCA2 functions in bypassing the replication
obstacles generated by CX-5461.
CX-5461 and CX-3543 induced DNA damage is repaired by
HR pathway. In the absence of functional BRCA2, a higher
percentage of cells exhibited 53BP foci upon CX-5461 and
CX-3543 treatment than in BRCA2 proﬁcient cells (Fig. 2c).
Furthermore, stronger g-H2AX and RPA phosphorylation were
observed in BRCA2 / cells compared to BRCA2þ /þ cells by
Western blotting (Fig. 4a). RPA phosphorylation happened at
RPA2-pT21, a site associated with replication stress27. These
ﬁndings suggest that DNA damage is less efﬁciently repaired in
BRCA2 deﬁcient cells. Moreover, RAD51 foci were detected upon
CX-5461 and CX-3543 treatment (Fig. 2a). Most RAD51 foci
co-localized with g-H2AX foci, implying that the BRCA2/RAD51
complex localizes to damaged DNA and is directly involved in
repairing DNA damage generated by CX-5461 and CX-3543
(Supplementary Fig. 5e).
To evaluate whether CX5461-induced cell death in BRCA2
knockout cells is caused by unrepaired DNA damage, mitotic
chromosome spreads were examined to visualize chromosome
breaks and chromosome structure abnormalities. A 48 h
treatment with 10 8M CX-5461 had no effect on WT cells,
but signiﬁcantly induced more chromosomal abnormalities in
BRCA2 / HCT116 (Fig. 4b,c). Likely, the unrepaired DNA
damage kills BRCA2 / cells. We further compared the kinetics
of repairing CX-5461 associated DNA damage in BRCA2þ /þ
and BRCA2 / cells. We pulse treated cells with 10 8M
CX-5461 for 2 h, then washed out drug and examined DNA
damage recovery. In WT, 72 h after drug pulse treatment, the
percentage of cells with 53BP1 foci was signiﬁcantly reduced in
comparison with their initial induction at 2 h (Fig. 4d,e). In
BRCA2 knockout cells, 53BP1 foci were not signiﬁcantly reduced
at 72 h and remained higher than no-drug baseline. These results
suggest the important role of BRCA2 in repairing CX-5461
induced DNA damage, and that compromised DNA damage
repair in the absence of BRCA2 will lead to lethality.
CX-5461 is a G-quadruplex stabilizer in the human genome.
CX-3543 has been shown to have G4 binding/stabilizing
activity16. This prompted us to examine whether CX-5461, which
has a related structure, is capable of binding and stabilizing G4
forming sequences. We performed a FRET-melting assay with
these compounds using DNA oligonucleotides comprising three
different G4 forming sequences (c-MYC, ckit1 and h-Telo)28 and
a control dsDNA sequence. In these experiments a known G4
binding and stabilizing small molecule, PDS29, was used as a
positive control. Both CX-5461 and CX-3543 displayed an
increased melting temperature (DTm) (415 C) in the presence
of 1 mM of either compound (Fig. 5a). Conversely, poor
stabilization and non-speciﬁc binding proﬁles were recorded
when treating a dsDNA forming sequence with CX-5461 or
CX-3543 (Fig. 5a), suggesting that both compounds can
selectively bind and stabilize G4 structures over the canonical
double helical DNA. In addition, the stabilization of the G4
structure by these compounds was not affected in the presence of
competitor dsDNA up to 50mol equiv. of excess (Supplementary
Fig. 6a,b), further conﬁrming that CX-5461 and CX-3543 are
selective G4 binders. In contrast, BMH-21 revealed no detectable
G4 binding or stabilization (Fig. 5a). To assess the ability of
stabilized G4 sequences to stall a DNA polymerase, we performed
an in vitro DNA polymerase extension/processivity assay30.
Strikingly, same as PDS, both CX-5461 and CX-3543 increased
DNA polymerase stalling selectively at the G4 site in the cKit1
template (Fig. 5b).
Next, we investigated whether CX-5461 and CX-3543 have G4
stabilization properties in a cellular environment, by performing
immunoﬂuorescence with the G4 selective antibody BG4 (ref. 31)
in HCT116 WT cells after incubation with 100 nM CX-5461 or
CX-3543 for 24 h. Notably both CX-3543 and CX-5461 showed a
signiﬁcant increase of nuclear BG4 foci (Fig. 5c), suggesting that
both compounds can trap and stabilize G4 structures in vivo at
nanomolar concentrations. We also measured the co-localization
of DNA damage 53BP1 foci and BG4 foci with and
without CX-5461/CX-3543, and found signiﬁcantly increased
co-localization in the presence of CX drugs and PDS in contrast
to no drug control and doxorubicin treatment (Fig. 5d).
To test directly whether chromosome destabilization by
CX-5461 is dependent on G4 structures, we performed a modiﬁed
gross chromosomal rearrangement (GCR) assay in yeast32, with a
known G4 DNA prone site, or a non-G4 forming G-rich control
sequence inserted near the selectable markers (Fig. 6a). By using a
sensitized background bearing the pif1-m2 allele, we found
CX-5461 signiﬁcantly increased GCR events compared to the
G-rich but non-quadruplex-forming control (Fig. 6a). Untreated
cells were not signiﬁcantly different from each other. In a human
cell system, we investigated the effect of CX-5461 on the integrity
of telomeres, loci enriched with G4 structures. Telomere FISH
results show an increased frequency of telomere defects in both
BRCA2þ /þ and BRCA2 / HCT116 cells after exposure to
CX-5461, and this defect was more prominent in BRCA2 /
cells (Fig. 6b). Collectively, these data support CX-5461 as a G4
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stabilizer and induces genome instability speciﬁcally at G4
sequences in both human and yeast cells.
In order to identify the targets of CX-5461 at a whole-genome
level, we performed chromatin immunoprecipitation (ChIP) of
RAD51 in U2OS followed by high throughput sequencing
analysis (ChIP-seq), as RAD51 is able to form chromatin-bound
foci in CX-5461-treated cells (Fig. 2a). We classiﬁed the G4
overlapping peaks as unique peaks (present in only one biological
replicate) and reoccurring peaks (present in more than one
biological replicate). More reoccurring peaks were obtained from
RAD51-ChIP under CX-5461 treatment (mean 2,816 peaks)
compared with RAD51-ChIP with vehicle control (mean 65 peaks)
or IgG-ChIP (mean 267 peaks) under the same concentration of
CX-5461 (Fig. 6c, Supplementary Tables 8 and 9). We also found
that the reoccurring peaks for RAD51-ChIP under CX-5461
treated condition contained more G4 sites (Fig. 6d, Supplementary
Fig. 6d–f) per peak. These results support the notion that CX-5461
induced DNA damage is repaired by the RAD51 pathway
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and the damage loci are enriched at G4 sequences in human
genome.
Genotype speciﬁc sensitivity to CX-5461 in human and model
systems. NHEJ is another important DSB repair pathway parallel
to the HR pathway. To clarify the role of the NHEJ pathway in
response to CX-5461 and other G4 stabilizers, we investigated the
effect of CX-5461 in cells knocked out of DNA-dependent protein
kinase catalytic subunit (DNA-PKcs, encoded by PRKDC), which
is a key component of the NHEJ pathway in mammalian cells.
The IC50 for CX-5461 decreasedBseven-fold (95% CI, 2.2–22.0)
in PRKDC / cells compared with PRKDCþ /þ cells (Fig. 7a,
Supplementary Fig. 7a). The involvement of the NHEJ pathway in
repairing G4-associated DNA damage is further strengthened by
the results from LIG4 proﬁcient and deﬁcient isogenic cells. Both
CX-5461 and PDS have higher drug sensitivity in LIG4 /
HCT116 cells compared with LIG4þ /þ HCT116 cells (Fig. 7b).
However, consistent with the result from the paper of Zimmer
et al.6, knocking down 53BP1 did not affect CX-5461 sensitivity
(Supplementary Fig. 7c,d). Thus, the NHEJ pathway is involved in
DNA damage repair when treated with G4 stabilizers, but 53BP1
is not required for this process. Furthermore, 53BP1 and BRCA1
double knockdown cells showed reduced sensitivity to CX-5461
than did BRCA1 single knockdown cells, but as compared with
non-targeting control, double knockdown cells were still more
sensitive to CX-5461 (Supplementary Fig. 7d). The role of
different genes in NHEJ pathway in regards to G4 resolution
needs further analysis.
In order to discover additional genotypes important for
CX-5461/CX-3543 drug response, we took advantage of the easy
handling of drug screens in the model organism Caenorhabditis
elegans. We examined a panel of B100 DNA damage response
mutant strains in C. elegans, using a qualitative chronic exposure
assay (Supplementary Table 2), and a quantitative acute exposure
assay (Fig. 7c). In addition to brc-2, loss of genes involved in
replication-associated repair and resolution of G4 structures
(mus-81, rfs-1, polq-1, helq-1, rtel-1) conferred increased
sensitivity to CX-5461. The Mus81 endonuclease has been
implicated in the replication fork restart and the resolution of
recombination intermediates33. The RAD51 paralog rfs-1 and the
helq-1 helicase respond to replication fork blocking lesions but
not to DNA double strand breaks11. polq-1 plays a major role
in microhomology-mediated end-joining and the repair of
replication associated DSBs34. Taken together, these data
support the involvement of additional DNA repair pathways in
CX-drug response, as has been noted in the context of G4
structures in model organisms35.
To further characterize the spectrum of CX-5461/CX-3543
cytotoxicity and contrast with Olaparib and BMH-21, we
measured the anti-proliferative effect of CX-5461/CX-3543,
BMH-21 and Olaparib across 50 well-characterised breast cancer
cell lines36 (Fig. 7d). Triple negative breast cancer (TNBC) cell
lines with mutation or low expression in HR pathway genes
(BRCA1/2 and RAD51) (BT20, CAL51, HCC1806, HCC1395,
MDA-MB-436, MDA-MB-468, HCC38)36 (Supplementary Table 4)
are more sensitive to CX-5461/CX-3543 (IC50r10 7M). TNBC
cell lines with deﬁciency (mutations or low expression) in other
DNA damage repair genes, such as, ATM, ATR and BARD1 also
exhibit higher sensitivity to CX-5461/CX-3543 (CAL120, HCC1187,
HBL100, HCC1143, HS578T, MDA-MB-231, SKBR7, SW527). Two
Her2 subtype cell lines show high sensitivity to CX5461 (HCC1954,
CAL-148), however both cell lines harbour a BRCA1 mutation
and low expression of FANCL in HCC1954, RAD50, and PTEN
mutations in CAL-148. These results are consistent with the
observation that CX-5461 is selectively active in BRCA1, BRCA2
deﬁcient cancers, and suggest that other DNA damage repair
pathways may also result in increased sensitivity to G4 stabilizers.
Furthermore, the sensitivity pattern of these breast cancer cell lines
to CX-5461/CX-3543 only partially overlaps that of cisplatin
and Olaparib, suggesting CX-5461/CX-3543 may be effective for
chemo-resistant cancers.
CX-5461 kills BRCA deﬁcient and chemo-resistant PDX
tumours. The signiﬁcant synthetic lethality of CX-5461 with
BRCA in vitro motivated us to determine whether a therapeutic
window could be seen in vivo in xenograft models. The antitumor
activity of CX-5461 was evaluated in NOD/SCID/IL-2g /
immunodeﬁcient mice with tumours subcutaneously engrafted
from HCT116 isogenic cell line pairs. Strikingly,
CX-5461 treatment substantially and signiﬁcantly inhibited the
growth rate of tumours formed from two BRCA2 deﬁcient
HCT116 cell lines (B18 and B46), in a dose-dependent manner
(Fig. 8a, Supplementary Fig. 8a). Tumour growth of the BRCA2
deﬁcient tumours remained suppressed for 10–20 days after
ceasing oral dosing with CX-5461 (Fig. 8a, vertical dashed lines).
In marked contrast, no tumour growth inhibition was observed
on tumours derived from BRCA2 proﬁcient HCT116 cells under
the highest dosage. As a consequence, CX-5461 greatly extended
the survival time of the mice bearing tumours derived from
BRCA2 knockout cells (Fig. 8c). At all tested schedules, CX-5461
was well tolerated as judged by minimal effect on animal body
weight (Supplementary Fig. 8a,b). Stronger tumour growth
inhibition to BRCA2 deﬁcient than BRCA2 WT cancers was also
observed in xenograft model with tumours formed by DLD1
isogenic cell line pairs (Fig. 8b,d).
To address the relationship of CX-5461 activity to standard
of care chemotherapy in polyclonal tumours, the activity of
CX-5461 was further tested in PDX models, beginning with
taxane resistant TNBC PDX tumours. Three different patient
tumours were compared initially: two containing deleterious
BRCA1 or BRCA2 mutations and one wild type status. All three
patients had received a taxane prior to tumour sampling.
Compared to vehicle control, CX-5461 reduced the tumour
growth of all three PDX tumours, (Fig. 8e), but the inhibition
of BRCA1 or BRCA2 deﬁcient PDX tumours (CTG-0012 and
CTG-0888) was much greater than on BRCA WT PDX tumour
(CTG-1019). We also observed that, CTG-0012 exhibited a weak
response to Olaparib but was very sensitive to CX-5461, showing
that CX-5461 activity spectrum may in some cases transcend that
of Olaparib. The combination effect of CX-5461 and Olaparib is
similar to CX-5461 alone in these PDX models.
We next evaluated CX-5461 in a platinum-pretreated
TNBC PDX (Fig. 8f). PDX CFIB-NB02 was generated from a
metastatic lesion biopsy from a heavily pretreated TNBC patient
(including platinum) with BRCA1 germline missense mutation.
The administration of CX-5461 resulted in dramatic tumour
regression with efﬁcacy comparable with carboplatin. PDX
CFIB-70620 was generated from a TNBC patient pretreated
with anthracycline/taxane chemotherapy with BRCA2 germline
mutation who had minimal response to cisplatin in the metastatic
setting (Supplementary Table 3). Again, CX-5461 signiﬁcantly
reduced the tumour growth in this PDX model. Taken together,
these data show that while CX-5461 activity spectrum partially
overlaps that of PARP inhibitors and platinum salts in HR
deﬁcient tumours, CX-5461 exhibits additional activity in some
tumours resistant to these agents.
Discussion
We have discovered two related small molecule drugs CX-5461
and CX-3543 that are able to selectively kill BRCA1/2 deﬁcient
cancer cells, one of which, CX-5461, is currently in advanced
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Figure 7 | CX-5461 effectively kills tumour cells deﬁcient for a number of DNA damage repair pathways. (a) PRKDC / HCT116 cells are more
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 cells are shown in Supplementary Fig. 7b. (c) Genotype speciﬁc sensitivity to CX-5461 in C. elegans. The percentage of viable embryos observed in the
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animals. (d) CX-5461/CX-3543 exhibits antiproliferative potency against a panel of breast cancer cell lines by SRB cytotoxicity assay. Heatmap represents
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cisplatin sensitivity (data from Sanger cell line project).
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stages of phase I safety testing in humans. This opens a new
therapeutic possibility for cancers with somatic inactivation of
HR pathway genes, which will be tested in a recently opened
phase I/II trial in BRCA1/2 deﬁcient patients (NCT02719977).
CX-5461 is structurally related to CX-3543 (Supplementary
Fig. 10) and other ﬂuorquinolones such as QQ58, whose
binding and stabilization of G4 structures by end-stacking has
been determined biophysically10. We found that both drugs,
in addition to inhibiting rRNA transcription as previously
published, potently induce replication dependent DNA damage,
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likely through binding and stabilization of G4 structure forming
DNA. We note that a potent, unrelated RNA pol I inhibitor
(BMH-21) which does not bind/stabilize G4 sequences, also does
not induce damage or exhibit synthetic lethality, showing that
RNA pol I transcription inhibition is not required for the
mechanism.
Upon treatment with CX-5461 and CX-3543, G4 structures are
signiﬁcantly induced and accompanied by a dramatic increase of
DNA damage foci in cells. BRCA deﬁcient cells are less
competent to bypass drug stabilized G4 structure during DNA
replication and less efﬁcient to repair G4 associated DNA
damage. As a consequence, the accumulated DNA damage in
BRCA deﬁcient cells leads to apoptosis (Supplementary Fig. 9).
Besides the HR pathway, the repair of CX-5461 and CX-3543
generated DNA damage also relies on the NHEJ pathway. We
analysed CX-5461 response of three genes in the NHEJ pathway:
DNA-PK, LIG4 and 53BP1. DNA-PK and LIG4 deﬁciency
increases CX-5461 and PDS sensitivity, but 53BP1 knocking
down has no effect. 53BP1 is not strictly required for NHEJ in
many settings. For example, 53BP1 is required for NHEJ in
class-switch recombination, but not required for NHEJ in V(D)
J recombination37,38. It is likely that 53BP1 doesn’t contribute to
NHEJ of G4 associated DNA damage. In addition, some other
genes in DNA replication and damage response are also involved
in the repair of CX-5461/CX-3543 generated DNA damage.
Mutation of ATM, ATR, BARD1, downregulation of genes in
FANC pathway are associated with high efﬁcacy to CX drugs in
in vitro drug sensitivity assays. These results suggest the potential
application of CX-5461 in treating cancers bearing these
mutations.
The speciﬁc toxicity of CX-5461 and CX-3543 against
BRCA1/2 deﬁcient cells was seen in a number of cell lines of
different genetic backgrounds (colon, breast, ovary) and different
species origins (yeast, mouse and human). This is consistent with
recent data using probe compounds that stabilize G4 sequences,
suggesting that selective sensitivity occurs in HR deﬁcient
backgrounds6. CX-5461 has been engineered for superior
in vivo stability and pharmacokinetics and is presently in
advanced phase I trials for haematologic malignancies15.
Consistent with the in vitro activities observed, CX-5461
exhibited a wide therapeutic index of activity in BRCA2
knockout tumour cells in xenograft models, when compared
with isogenic wild type control cells. Furthermore, CX-5461 is
also effective in PDX models for chemo-resistant breast cancers,
including tumours relatively insensitive to PARP inhibition
and/or platinum salts. Our data thus suggest immediately
practical applications of CX-5461 in BRCA deﬁcient
tumours and possibly other tumours deﬁcient for DNA repair.
In particular, it is possible that the dose used to treat BRCA
deﬁcient cancers may be lower than that required to inhibit RNA
polymerase I and disrupt nucleolus function, because our data
suggest that BRCA deﬁcient cells are killed by CX-5461 at low
drug concentrations, which are not effective at inhibiting rDNA
transcription.
In summary, our study repurposes the application of CX-5461
and CX-3543, and likely other G4 stabilizers, in treating cancers
with deﬁciencies in BRCA pathway, NHEJ pathway, and other
genes in DNA damage repair and DNA replication.
Methods
Human cell lines, yeast and C. elegans strains. HCT116 BRCA2þ /þ cells and
BRCA2 / cells were described previously21. Mouse mammary tumour BRCA2
knockout cells (K14-Cre; Brca2F11/F11; p53F2-10/F2-10) and control mouse
mammary tumour BRCA2 proﬁcient cells (K14-Cre; Brca2wt/wt; p53F2-10/F2-10)
were from Dr Jos Jonkers’ lab and were cultured according to publication23.
DLD1 BRCA2 proﬁcient and BRCA2 knockout cells, HCT116 DNA-PK WT and
knockout cells, LIG4 WT and knockout cells were all from Horizon Discovery and
were grown in RPMI140 with 10% FBS and 2mM L-glutamine. PEO1 and C4-2
cells were from Toshiyasu Taniguchi’s lab and were grown in DMEM medium with
10% FBS and L-glutamine22. U2OS cells were from ATCC and were grown in
McCoy’s 5 A medium with 10% FBS and L-glutamine. All cell lines are mycoplasma
free and have been authenticated by STR or SNP proﬁling.
Disease subtypes and mutation status of breast cancer cell line panel in Fig. 7d
are extracted from publication36 and Cosmic (http://cancer.sanger.ac.uk/cell_lines),
and are summarized in Supplementary Table 4.
Nematode strains were maintained as described previously39. The strains used
are listed in Supplementary Table 2. Some strains were generated by the
International C. elegans Gene Knockout Consortium and the National Bioresource
Project of Japan. The genotypes and background of all the yeast strains used in this
study are as previously described40.
Cell line xenograft mouse model. Animal procedures were approved by the
University of British Columbia animal protection committee. Six to ten week old
female NOD/SCID/IL-2g / immunodeﬁcient mice were subcutaneously
engrafted with 2 106 tumour cells for BRCA2 proﬁcient and 5 106 cells for
BRCA2 knockout cells. CX-5461 was dissolved in 50mM NaH2PO4, pH4 for
xenograft application. Established tumours were randomized into vehicle and
CX-5461-treated groups. Tumour measurement was performed by external caliper
and tumour volume was calculated using the formula [V¼ 1/2 (lengthwidth2)].
Mouse weight was measured every 3 days. CX-5461 was administered through oral
gavage once every three days with three doses: 12.5mg kg 1, 25mg kg 1 and
50mg kg 1 for tumours formed from HCT116 cells. For mice bearing tumours
from DLD1 cells, CX-5461 was administered orally at 50mg kg 1 once every three
days. Mice were sacriﬁced when tumour size reached 1,000mm3, or when all other
mice in a given genotype/drug dose group had been sacriﬁced, up to a maximum of
90 days post-xenograft.
Patient-derived xenograft model. BRCA status and clinical characteristic
of patient tumours in Fig. 8 are listed in Supplementary Table 3. Mice
PDX experiments for model CFIB-NB02 and CFIB-70620 were approved by
University Health Network Research Ethics Board in Toronto #15-9481-CE.
PDX experiments for Model CTG-1019, CTG-0012, and CTG-0888 were
approved by Ofﬁce of Laboratory Animal Welfare, NIH (A4614-01).
For Model CTG-1019 (WT), vehicle control was administered intravenously
each week for 28 days (IV QWx4), Olaparib (50mg kg 1 dose 1)
Figure 8 | CX-5461 selectively suppresses growth of BRCA deﬁcient tumours in murine xenografts and chemo-resistant PDX model. (a,b) The effect of
CX-5461 on tumor growth with xenografted tumours from isogenic WTand BRCA2 knockout HCT116 (a) and DLD1 (b) cells. For HCT116 xenograft model,
three drug doses were administered at 12.5mg kg 1, 25mg kg 1 and 50mg kg 1 together with vehicle control. For DLD1 xenograft model, CX-5461 was
administered at 50mg kg 1. Vertical dashed lines show the end of drug treatment. Each coloured line represents individual mouse in a. Solid lines in b
represent the mean tumour volume with 95% CI (shown by shadow around solid lines) from a linear model ﬁtted to the tumour volumes. (c,d) The
administration of CX-5461 greatly extended the survival of mice with tumours from BRCA2 deﬁcient but not BRCA2 proﬁcient in xenograft models with
tumours formed from HCT116 cells (c) and DLD1 cells (d). The survival of mice in experimental panel is shown as moribund-free survival time post
randomization. The signiﬁcance of survival differences is indicated with the log rank test (See Statistical methods). Dose-dependent trend signiﬁcance is
indicated with the log rank test for trend. (e) CX-5461 is effective for taxane resistant BRCA1/2 deﬁcient TNBC in PDX model. Growth curve of tumours
grafted from individual patients with BRCA1 and BRCA2 WT (CTG-1019), BRCA1 germline and BRCA2 somatic mutation (CTG-0888, gBRCA1m/sBRCA2m),
and BRCA2 germline and BRCA1 somatic mutation (CTG-0012, sBRCA1m/gBRCA2m). Tumour volume average curves (lines) with pointwise 95% CIs
(shaded regions) are shown. Mice were treated with vehicle, Olaparib, CX-5461 or the combination of Olaparib and CX-5461. See Supplementary Fig. 8c for
body weight and drug dosing schedule. (f) CX-5461 is effective in cisplatin pretreated and BRCA1/2 deﬁcient TNBC in PDX model. Tumour volume average
curves (lines) with pointwise 95% CIs (shaded regions) are shown. Tumours are grafted from patients with BRCA1 (CFIB-NB02), and BRCA2 (CFIB-70620)
germline mutation. See Supplementary Fig. 8d for body weight and drug dosing schedule.
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was administered orally each day for 28 days (PO QDx28), CX-5461
(125mg kg 1 dose 1) was administered intravenously each week for 14 days
(IV QWx3), and Olaparib (50mg kg 1 dose 1) was administered orally each day
for 17 days (PO QDx17) in combination with CX-5461 (125mg kg 1 dose 1)
administered intravenously each week for 14 days (IV QWx3) to the groups
respectively.
For Model CTG-0012 (sBRCA1m/gBRCA2m), vehicle control was
administered intravenously each week for 28 days (IV QWx4), Olaparib
(50mg kg 1 dose 1) was administered orally each day for 28 days (PO QDx28),
CX-5461 (125mg kg 1 dose 1) was administered intravenously each week for 7
days (IV QWx2), and Olaparib (50mg kg 1 dose 1) was administered orally each
day for 10 days (PO QDx10) in combination with CX-5461 (125mg kg 1 dose 1)
administered intravenously each week for 7 days (IV QWx2) to the groups
respectively.
For Model CTG-0888 (gBRCA1m/sBRCA2m), vehicle control was
administered intravenously each week for 28 days (IV QWx4), Olaparib
(50mg kg 1 dose 1) was administered orally each day for 28 days (PO QDx28),
CX-5461 (62.5mg kg 1 dose 1) was administered intravenously each week for 28
days (IV QWx4) and Olaparib (50mg kg 1 dose 1) was administered orally each
day for 28 days (PO QDx28) in combination with CX-5461 (62.5mg kg 1 dose 1)
administered intravenously each week for 28 days (IV QWx4) to the groups
respectively.
For PDX model CFIB-NB02 (gBRCA1m) and CFIB-70620 (gBRCA2m), vehicle
(50mM NaH2PO4, pH 4) and CX-5461 (50mg kg 1) were administered once
every 3 days through oral gavage. Carboplatin was administered at 7.5mg kg 1
through IP once every week.
siRNA sequences. siRNA for BRCA2: Target DNA sequence: AACAA-
CAATTACGAACCAAAC, dTdT overhang. Other siRNAs are ordered from
Dharmacon.
Drugs and antibodies. Drugs and antibodies used in this study are listed in
Supplementary Table 1
WST-1 assay and clonogenic assay. Clonogenic assay was performed as
previously described21. Drug incubation time for clonogenic assay is 12 days. For
clonogenic assay after siRNA knocking down, the cells were knocked down with
siRNA one day before plating for single cells and treated with drugs. WST-1 assay
was performed according to the protocol provided by manufactory (Roche,
Catalogue number 11644807001). Wild type and BRCA2 knockout cells were
plated in 96-well plates either untreated or treated with drug continuously during
the indicated time before WST-1 assay. Drug incubation time in Fig. 1 is 6 days and
in Fig. 7 is 4 days except speciﬁed. Absorbance was read with the microplate reader
SpectraMax 3 (Molecular Devices, Sunnyvale, CA, USA).
SRB assay. Cells were seeded into 96-well plates and incubated with drugs for 5
days before ﬁxation with 10% TCA, and being washed with tap water and air dry.
Then the dried cells were stained with SRB reagent and incubated 30min at
room temperature in the dark. Plates were later washed with 1% acetic acid and
completely air dry, then solubilised with 10mM Tris. The intensity of the stained
cells was read at 570 nm on spectrophotometer.
Immunoﬂuorescence of DNA damage foci. For detection of RPA2, RAD51 foci
cells were extracted with CSK buffer (100mM NaCl, 300mM sucrose, 3mM
MgCl2, 10mM PIPES (pH 6.8), with proteinase inhibitors) for 4min before
ﬁxation. For g-H2AX and 53BP1 foci visualization, cells were ﬁxed with 4%
paraformaldehyde in TBS (50mM Tris-Cl, pH 7.5, 150mM NaCl) without
extraction, and then permeabilized with methanol for 1min on ice. Cells were
blocked in blocking buffer (2% BSA, 0.2% Tween-20 in TBS) for 30min before
incubation with primary antibody overnight. Secondary antibodies were incubated
for 1 h. Because of background staining, damage foci positive cells were deﬁned as
cells with g-H2AX fociZ5, 53BP1 fociZ3, RAD51 fociZ5, and RPA fociZ5.
Immunoﬂuorescence of G4 detection. For detection of G4, HCT116 WT cells
were treated with 100 nM of CX-5461 or CX-3543 for 24 h, then ﬁxed with 4%
paraformaldehyde in PBS (15min) and permeabilized with 0.1% Triton-X
(20min). Cells were blocked with 5% dry milk in PBS for 1 h before incubation
with primary, secondary and ternary antibody for 1 h each at 37 C.
Western blotting. Cells were directly lysed in RIPA buffer with protease inhibitors
and phosphatases inhibitors. Brief sonication was applied to disrupt DNA, before
boiling in laemmli sample buffer for 10min at 90 C. 10 mg protein was loaded in
each well of SDS–PAGE. For the detection of BRCA1/2 and 53BP1, 1 million cells
per sample were loaded to 6% SDS–PAGE.
Cell fractionation. 1 million cells per sample were washed once with PBS and then
lysed on ice with CSK buffer (100mM NaCl, 300mM sucrose, 3mM MgCl2,
10mM PIPES (pH 6.8), 0.5% Triton X-100 with proteinase inhibitors, and
phosphatase inhibitors) for 15min. Then the cells were equally separated to three
vials: one for whole cell lysate (WC), one for free cytoplasmic and nucleoplasmic
proteins (FCN) and one for chromatin-bound proteins (CB). After centrifugation
(900 g, 5min at 4 C), the FCN fraction is in the suppernant and the CB fraction is
in the pellet. The WC and CB fractions were resuspended in RIPA buffer with
1 Laemmli sample buffer, then were boiled for 10–15min before loading to
SDS–PAGE.
Apoptosis assay. Apoptosis was assayed via Annexin V-FITC and propidium
iodide (PI) staining according to the manufacturer’s protocol (Invitrogen Carlsbad,
CA, USA, Catalogue number, A13201). HCT116 cells were treated with CX-5461
or vehicle for 72 h; then the percentage of apoptotic cells was analysed by ﬂow
cytometry. Early apoptotic cells are Annexin V positive and PI negative (lower
right quadrant in FACS proﬁle); late apoptotic and dead cells are Annexin V and PI
positive (upper right quadrant). 10,000 cells were counted for each sample.
Cell cycle analysis. Cells were treated with 10 mM EdU, a thymidine analogue, for
1 h prior to harvesting. Cells were then ﬁxed with 4% paraformaldehyde for 15min,
permeabilized with 0.5% Triton-X 100 in PBS for 20min and then incubated with
click-it cocktail according to manufacturers protocol (Invitrogen Carlsbad, CA,
USA, Catalogue number, C10420).
Cell cycle synchronization using a double thymidine block was carried out
according to a published paper41.
Mitotic index. The population of metaphase cells were identiﬁed by pH¼ 3 and PI
double staining and analysed by ﬂow cytometry. Cells were ﬁxed with 70% ethanol
and then blocked in TST (50mM Tris-base, pH 7.6, 0.9% NaCl, 4% FBS, 0.2%
Triton X-100) for 10min before incubation with anti-pH 3 antibody (Millipore
Cat. 06-570) for 1 h at room temperature. After washing with TST, secondary
antibody was added and incubated for 1 h. Before ﬂow cytometry, cells were
incubated with 10mgml 1 PI and Rnase A (100 mgml 1) for 10min.
Homologous recombination assay. HR was measure by using DR-GFP cell line
with transfected pCBA-(I-SceI)42.
Comet assay. Alkaline comet and neutral comet assays were performed according
to publication26. Images were collected by ﬂuorescence microscope. Comets were
analysed from at least 100 cells per each replica using software developed by
Dr Ralph E Durand for tail moments calculation43.
Chromosome spread. Cells were treated with or without CX-5461 for 2 days, and
then were arrested in mitosis with 3.3 mgml 1 Colcemid. Cells were arrested for
2.5 h, centrifuged for 5min at 3,500 r.p.m., resuspended in 1ml hypotonic sodium
citrate solution (0.5% Na-citrate in ddH2O) at concentration of 2 105 cells per ml
and incubated for 20min. 500ml 1ml of swelled cells were spun on positively
charged slides in a Shandon 4 cytospin (900 r.p.m., high acceleration for 10min),
ﬁxed with methanol and acetic acid mix (3:1) for 10min and staining was
performed by PI (1 mgml) for 30min. Spread chromosomes were visualized by
ﬂuorescence microscope at magniﬁcation of  1,000. Chromosome abnormalities
include breaks, acentric or dicentric chromosome, rings, radial chromosomes.
Telomere FISH. Chromosome spread was ﬁrst prepared, and then telomere FISH
was performed by following the protocol provided along with the Telomere PNA
FISH kit from DAKO (Cat. K5326).
DNA combing analysis. Cells are pulse-labelled with 25 mM CldU for 30min, then
washed with pre-warmed PBS and pulsed again with 125 mM IdU for 30min in the
presence of drug. After trypsinization, cells are resuspended in PBS at 3 106 cells
per ml. Cells are warmed at 37 for 5min, then added an equal volume of 1% low
melting point agarose solution, and poured into plug castor (BIO-RAD #170-3713).
The agarose embedded with cells are solidiﬁed at 4 C for 45min, then are eject
into ProK solution (1mgml 1 proteinase K in 500mM EDTA, 1% sarkosyl).
Proteinse K pre-digested are performed at 50 C for 30min before use.
Each agarose plug was stained with YOYO-1 (1 ml of YOYO-1 in 150ml TE50) at
room temperature for 30min. Plugs were washed three times in 10ml TE50 and
subsequently incubated in 2ml MES (7:3 v/v MES hydrate: MES sodium salt,
50mM, pH 5.7) and melted at 72 C for 15min. Silanized coverslips were
incubated in the melted agarose plug solution and DNA ﬁbres were combed onto
the coverslips at 710 mms 1. DNA was hybridized at 60 C for 90min, and
dehydrated sequentially in 70%, 90% and anhydrous ethanol. DNA was denatured
by incubation in 1M NaOH for 25min at room temperature. Cover slips with
combed DNA were incubating in block buffer (10% w/v albumin in PBS-T,
0.05% Tween-20, 2mM KH2PO4, 2.7mM KCl, 137mM NaCl, pH 7.4), anti-CldU
& anti-IdU solution (AbD Serotec MCA2060 and Becton Dickson 347580,
respectively, 1:40 dilution in blocking buffer), anti-ssDNA solution (Millipore
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MAB3034 1:50 dilution in blocking buffer), and anti-secondary solution (Alexa
Fluor 546 anti-mouse IgG1, Invitrogen A21123, 1:50 dilution, Alexa ﬂuor 648
anti-mouse IgG2, Invitrogen A21241, 1:50 dilution, and Alexa Fluor 488 anti-rat,
Invitrogen A11006) for 1 h at 37 C each time, with PBS-T washes between each
staining. ProLong Gold was added to each cover slip and coverslips were stored at
 20 C prior to imaging.
GCR assay. Yeast GCR assay was performed as previously described32. CX-5461
treatment time was 36–48 h. The GCR rates were calculated using the FALCOR
web server and MMS maximum likelihood method. The number of GCR events
(m) were used to determine the level of signiﬁcance (P value) with a student
two-tailed t-test44.
Yeast growth and RAD52-YFP imaging. Yeast growth curves in YPD and
Rad52-YFP imaging in synthetic complete media at 30 C were performed as
previously described45. The drugs were diluted in 50mM NaH2PO4 buffer
(CX-5461) and 1% DMSO (CX-3543).
C. elegans CX-5461 chronic sensitivity assays. 5 L1 larvae of each mutant strain
were picked to 50 ml of M9 buffer containing OP50, carbenicillin (50 mgml 1),
1 nystatin, 500 mM NaH2PO4 with and without 100mM CX-5461. Worms were
incubated for 4–6 days and F1 growth compared between wells with and without
CX-5461. A strain was scored as sensitive if there was an obvious growth difference
between wells with and without CX-5461 in three of three separate experiments.
C. elegans CX-5461 acute sensitivity assays. L4 stage animals were picked to
fresh plates and aged for 24 h so that the animals were 1-day-old adults on the day
of the experiment. Young adults were incubated in CX-5461 (in NaH2PO4) diluted
in M9 buffer containing OP50, carbenicillin (50mgml 1) and 1 nystatin for
B20 h. Following treatment, the animals were allowed to recover 1 h on OP50
containing NGM plates before being plated at ten per plate on NGM plates for a 4 h
interval (20–24 h post-treatment). The number of embryos laid during the 4 h
interval was counted and the number of arrested embryos versus hatching larvae
was counted 24 h later in order to calculate the percentage of progeny surviving
after treatment. All results were from at least 30 treated animals (three plates with
10 animals per plate).
RAD51 ChIP-seq. RAD51-ChIP was performed according to the published
protocol46 by using RAD51 antibody (Santa Cruz, Cat. 8349) after 24 h treatment
with or without CX-5461 (10 7M). Paired FASTQ ﬁles were obtained and adaptor
sequences were removed automatically with Trim Galore! (v0.4.1) [1], then aligned
with bowtie2 (v2.2.7) with default settings against hg19þ rDNA. After alignment,
only concordantly aligned pairs with a mapping quality of X30 were kept,
removing misaligned and ambiguously aligned reads. Supplementary Table 8
shows the number of reads going in, successfully mapped, and remaining after
ﬁltering.
Biological replicates for treated, untreated, and IgG runs were run through
MACS2 (v2.1.1) using the same replicate background untreated IgG libraries.
MACS2 was set to automatically detect fragment size, build the model, and output
all narrow peaks with a q-value ofr0.25. We then categorized peaks as those that
were reoccurring if it overlapped with at least one other peak (within 500 bp up and
downstream) in a biological replicate with the same background library. Peaks that
did not overlap with any other peaks are then referred to as ‘unique’ peaks. All
peaks were then ﬁltered by q-value, keeping only those with a q-value of r0.1.
G4 are deﬁned as PDS-induced sites from Chambers’ paper47 on either strand
that fall within the peaks ±500 bps.
Quantitative real-time reverse transcription PCR. RNA isolation and reverse
transcription has been described before21. Quantitative PCR was performed on an
ABI 7900HT system. In total, 45s pre-rRNA level was measured using primers
amplifying an internal transcribed spacer region as described in ref. 48 (forward
primer, GCC TTC TCT AGC GAT CTG AGA G; reverse primer, CCA TAA CGG
AGG CAG AGA CA) by sybrgreen analysis (Thermo Scientiﬁc, Cat. number,
K0221), and also using a published primers-probe set16 by Taqman assay (Applied
Biosystems, Cat. number, 4364338). Relative cDNA amounts were normalized to
ACTIN B and 18s rRNA. ACTIN B was detected by sybrgreen (forward primer,
ccaaccgcgagaagatga; reverse primer, ccagaggcgtacagggatag) and Taqman RT-PCR
assay (probe #64 from Roche). In total, 18s rRNA was evaluated by both sybrgreen
ampliﬁcation (forward primer, AAACGGCTACCACATCCA; reverse primer,
CCTCCAATGGATCCTCGT, amplifying a non-spacer region in 45s pre-rRNA)
and a Taqman primers-probe set (forward primer, cgattggatggtttagtgagg; reverse
primer, agttcgaccgtcttctcagc; prober #81 from Roche). Actinomycin treatment
(50 nm, 24 h) was used as a positive control for rDNA transcription inhibition.
BRCA2 and polR1B expression were analysed by Taqman approach. BRCA2
forward primer: gcaagatggtgcagagcttta; reverse primer: cttaactgctcttcactgaaataacc;
probe #84 from Roche. PolR1B forward primer: ttccagctttactgtgcaactt; reverse
primer: acccagccaaccatgaca; probe #18 from Roche.
FRET melting assay. FRET experiments were carried out with a 200 nM
oligonucleotide concentration. All DNA oligonucleotides were supplied by IBA
GmbH. The donor ﬂuorophore was 6-carboxyﬂuorescein (FAM) and the acceptor
ﬂuorophore was 6-carboxytetramethylrhodamine (TAMRA). The dual-labelled
oligonucleotides were annealed at a concentration of 400 nM by heating at 94 C
for 10min followed by slow cooling to room temperature at a controlled rate of
0.1 Cmin 1. 96-well plates were prepared by addition of 50 ml of the annealed
DNA solution to each well, followed by 50 ml solution of molecules CX-5461,
CX-3543 at the appropriate concentration.
Seven dual ﬂuorescently labelled DNA oligonucleotides were used in these ex-
periments: H-Telo (50-FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA-30),
C-kit1 (50-FAM-GGG AGG GCG CTG GGA GGA GGG-TAMRA-30), C-myc
(50-FAM-TGA GGG TGG GTA GGG TGG GTA A-TAMRA-30), ds-DNA
(50-FAM-TAT AGC TAT A-HEG-T ATA GCT ATA-TAMRA-30) which is a
dual-labelled 20-mer oligonucleotide comprising a self-complementary sequence
with a central polyethylene glycol linker able to fold into a hairpin. The competitor
was an unlabelled 26-mer oligonucleotide (50-CAA TCG GAT CGA ATT CGA
TCC GAT TG-30). A total of 100 mM stock solutions of oligonucleotides were
prepared in molecular biology grade DNase-free water. Further dilutions were
carried out in 60mM potassium cacodylate buffer, pH 7.4.
For the competition experiments, competitor was added to the ﬂuorescently
labelled quadruplex oligonucleotides sequences at an excess of 50mol equiv. and
annealed in the same solution. Measurements were made in triplicate with an
excitation wavelength of 483 nm and a detection wavelength of 533 nm.
Polymerase stop assay. WT cKit1 template: TCT GCT TTG GGA ACC CGA
GAG GAG CGC TTA TAG GGA GGG CGC TGG GAG GAG GGA GGA GAC
TCA GCC GAG CAG CCG AGC ACT CTA GCT CTA G MUT cKit1 template:
TCT GCT TTG GGA ACC CGA GAG GAG CGC TTA TAG AGA GAG CGC
TGA GAG GAG AGA GGA GAC TCA GCC GAG CAG CCG AGC ACT CTA
GCT CTA G
Primer: [Cyanine5] CTA GAG CTA GAG TGC TCG GC
8 ml of 1 NEB buffer 1 supplemented with 100mM KCl containing 500 nM of
template oligo and 50 nM of primer was added to a PCR tube. The solution was
heated to 95 C for 5min then allowed to cool to room temperature. 1 ml of
G4-stabilizing ligand (in a 1% DMSO/water solution) was added to the annealed
material. This solution was incubated at 37 C for 30min. Then 1 ml of the
polymerase mix (89 ml of 1 NEB buffer 1, 10ml of 10mM NEB dNTP mix, and
1 ml of NEB Klenow fragmentexo ) was added. The mixture was incubated at 37 C
for 2 h. The reaction was stopped by addition of 20 ml of 2 NEB orange gel
loading dye and heated to 95 C for 5min. To a 15% TBE-Urea gel (Precast
Novex), was added 7 ml of the quenched solution. Gel running conditions were
300V for 35min. The gel was scanned on a GE Typhoon imager set to detect Cy5.
The lane pixel density quantitation was processed using ImageJ software. Fractional
peak area was quantiﬁed by ﬂuorescence intensity of the dashed box area over the
total ﬂuorescence on the lane. The appearance of smaller bands indicates the stall
of DNA polymerase.
Statistical methods.
R Session information:
R version 3.2.0 (2015-04-16) was used for all statistical analysis of data.
Platform: x86_64-apple-darwin13.4.0 (64-bit)
Running under: OS X 10.10.3 (Yosemite)
locale:
[1] C
attached base packages:
[1] stats graphics grDevices utils datasets methods base
other attached packages:
[1] nlme_3.1-120 gdata_2.16.1
loaded via a namespace (and not attached):
[1] compiler_3.2.0 tools_3.2.0 grid_3.2.0 gtools_3.4.2
[5] lattice_0.20-31
Dose response curve ﬁtting for WST-1 assay. Where sigmoid curves were
appropriate for dose response analysis, a four-parameter logistic regression curve
was ﬁtted to the data using the R function ‘nlme’. An IC50 was estimated, the
difference in IC50 values was calculated for conditions with and without drug.
The set of differences was tested using the Student’s paired t-test.
Where logistic model ﬁts were not available, typically due to lack of ﬁt when the
number of drug doses assayed did not adequately cover the descending portion of
the sigmoid curve, rank regression was used to compare the drug response for the
multiple groups comprising the experimental condition. The entire experiment’s
normalized intensity values were ranked from smallest to largest, and their
normalized intensity values replaced by their rank values49. A standard linear
model of rank versus categorized drug dose was ﬁtted for each experimental
condition, with differing slope and intercept for each experimental condition,
yielding a standard two-way ANOVA design. Drug dose was categorized to allow
the linear model to reasonably ﬁt the non-linear sigmoid shape of the data.
Differences in response to drug dose were assessed by testing the experimental
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factor using a standard F-test comparing the ANOVA models with and without the
experimental condition variable. Dose response curves were estimated using
Friedman’s super-smoother50 but IC50s were not estimable.
Survival analysis for xenograft study. Mice showing tumour growth to 200 cubic
millimetres were randomized to treatment groups. After randomization, mice were
followed until tumour growth reached 1,000 cubic millimetres or until all other
mice within each genotype had been sacriﬁced, up to a maximum of 90 days of
observation. Thus the survival analysis endpoint was time to sacriﬁce due to
maximum allowable tumour volume. Mice who lived without reaching maximum
allowable tumour volume and were subsequently sacriﬁced were considered
censored at their sacriﬁce date for the purposes of survival analysis.Survival data
were displayed graphically using Kaplan–Meier curves. Time to event differences
were assessed using the log-rank test51. Log-rank analysis and test for trend were
carried out for the control group and three drug dose groups within each cell line
xenograft and genotype. The trend test was conducted using the log-rank test for
trend52. All analyses were conducted using the R statistical software package53.
qPCR assay statistical analysis. qPCR Ct values were modelled using standard
Gaussian linear models with categorical variables for the experimental conditions
of interest, yielding two-way (for example, experiments comparing effects between
BRCA2 genotypes) and three-way (for example, experiments comparing BRCA2
genotype responses within differing treatment conditions) ANOVA designs.
Additional categorical variables indicating experimental plate and multiple
loading controls were also included in the models, to allow model adjustment for
shifts in Ct values from experiment to experiment and among loading controls.
Experimental effects were assessed using F-tests. Effect magnitudes and 95% CIs on
the log2 scale were obtained from delta-delta-Ct calculations from the linear
models. Fold change estimates were obtained via exponents of the form
2 (delta-delta-Ct). When assessing multiple gene targets, resultant F-test P values
were adjusted for multiple comparisons using the Benjamini–Hochberg method54.
All analyses was conducted using the R statistical software package53.
Comet assay statistical analysis. Mixed effects models compare the means of the
sets of cells in each experiment and condition and obtain variance estimates
reﬂecting between experiment and condition means rather than between individual
cell measurements, with degrees of freedom reﬂecting the number of conditions
and experiments rather than the total number of cells assayed.
Raw tail moment values were modelled using a linear mixed effects model55.
Family-wise 95% CIs (ie, adjusted for multiple comparisons56 for experimental
condition contrasts of interest were calculated and displayed graphically.
Data availability. The authors declare that the dataset and computer code
generated during and/or analysed during the current study are available from the
corresponding author on reasonable request. RAD51-ChIP data have been
deposited in the Genbank GEO database (http://www.ncbi.nlm.nih.gov/geo/) under
accession codes GSE90967. G4 sequences in human genome were obtained from
the paper by Chamber et al.47, and available under the accession code GSE63874.
All other remaining data are available within the Article and Supplementary Files,
or available from the authors upon request.
References
1. Breast Cancer Linkage, C. Cancer risks in BRCA2 mutation carriers. J. Natl
Cancer Inst. 91, 1310–1316 (1999).
2. Wooster, R. et al. Identiﬁcation of the breast cancer susceptibility gene BRCA2.
Nature 378, 789–792 (1995).
3. Davies, A. A. et al. Role of BRCA2 in control of the RAD51 recombination and
DNA repair protein. Mol. Cell 7, 273–282 (2001).
4. Schlacher, K. et al. Double-strand break repair-independent role for BRCA2 in
blocking stalled replication fork degradation by MRE11. Cell 145, 529–542
(2011).
5. Bhatia, V. et al. BRCA2 prevents R-loop accumulation and associates with
TREX-2 mRNA export factor PCID2. Nature 511, 362–365 (2014).
6. Zimmer, J. et al. Targeting BRCA1 and BRCA2 deﬁciencies with
G-quadruplex-interacting compounds. Mol. Cell 61, 449–460 (2016).
7. Huppert, J. L. & Balasubramanian, S. Prevalence of quadruplexes in the human
genome. Nucleic Acids Res. 33, 2908–2916 (2005).
8. Todd, A. K., Johnston, M. & Neidle, S. Highly prevalent putative quadruplex
sequence motifs in human DNA. Nucleic Acids Res. 33, 2901–2907 (2005).
9. Ha¨nsel-Hertsch, R. et al. G-quadruplex structures mark human regulatory
chromatin. Nat. Genet. 48, 1267–1272 (2016).
10. Duan, W. et al. Design and synthesis of ﬂuoroquinophenoxazines that interact
with human telomeric G-quadruplexes and their biological effects. Mol. Cancer
Ther. 1, 103–120 (2001).
11. Ward, J. D., Barber, L. J., Petalcorin, M. I., Yanowitz, J. & Boulton, S. J.
Replication blocking lesions present a unique substrate for homologous
recombination. EMBO J. 26, 3384–3396 (2007).
12. Youds, J. L., O’Neil, N. J. & Rose, A. M. Homologous recombination is required
for genome stability in the absence of DOG-1 in Caenorhabditis elegans.
Genetics 173, 697–708 (2006).
13. McLuckie, K. I. et al. G-quadruplex DNA as a molecular target for induced
synthetic lethality in cancer cells. J. Am. Chem. Soc. 135, 9640–9643 (2013).
14. Derenzini, M. et al. Nucleolar size indicates the rapidity of cell proliferation in
cancer tissues. J. Pathol. 191, 181–186 (2000).
15. Bywater, M. J. et al. Inhibition of RNA polymerase I as a therapeutic strategy to
promote cancer-speciﬁc activation of p53. Cancer Cell 22, 51–65 (2012).
16. Drygin, D. et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA
biogenesis. Cancer Res. 69, 7653–7661 (2009).
17. Drygin, D. et al. Targeting RNA polymerase I with an oral small molecule
CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer
Res. 71, 1418–1430 (2011).
18. Peltonen, K. et al. A targeting modality for destruction of RNA polymerase I
that possesses anticancer activity. Cancer Cell 25, 77–90 (2014).
19. Negi, S. S. & Brown, P. rRNA synthesis inhibitor, CX-5461, activates
ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase
and induces apoptosis. Oncotarget 6, 18094–18104 (2015).
20. Li, L. et al. CX-5461 induces autophagy and inhibits tumor growth via
mammalian target of rapamycin-related signaling pathways in osteosarcoma.
OncoTargets Ther. 9, 5985–5997 (2016).
21. Xu, H. et al. Up-regulation of the interferon-related genes in BRCA2 knockout
epithelial cells. J. Pathol. 234, 386–397 (2014).
22. Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2
mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69, 6381–6386
(2009).
23. Evers, B. et al. Selective inhibition of BRCA2-deﬁcient mammary tumor cell
growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916–3925 (2008).
24. Chen, J. J., Silver, D., Cantor, S., Livingston, D. M. & Scully, R. BRCA1, BRCA2,
and Rad51 operate in a common DNA damage response pathway. Cancer Res.
59, 1752s–1756s (1999).
25. Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection pathway
connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell
22, 106–116 (2012).
26. Olive, P. L. & Banath, J. P. The comet assay: a method to measure DNA damage
in individual cells. Nat. Protoc. 1, 23–29 (2006).
27. Toledo, L. I. et al. ATR prohibits replication catastrophe by preventing global
exhaustion of RPA. Cell 155, 1088–1103 (2013).
28. Mergny, J. L. & Maurizot, J. C. Fluorescence resonance energy transfer as a probe
for G-quartet formation by a telomeric repeat. Chembiochem 2, 124–132 (2001).
29. Rodriguez, R. et al. Small-molecule-induced DNA damage identiﬁes alternative
DNA structures in human genes. Nat. Chem. Biol. 8, 301–310 (2012).
30. Weitzmann, M. N., Woodford, K. J. & Usdin, K. The development and use of a
DNA polymerase arrest assay for the evaluation of parameters affecting
intrastrand tetraplex formation. J. Biol. Chem. 271, 20958–20964 (1996).
31. Bifﬁ, G., Tannahill, D., Miller, J., Howat, W. J. & Balasubramanian, S. Elevated
levels of G-quadruplex formation in human stomach and liver cancer tissues.
PLoS ONE 9, e102711 (2014).
32. Paeschke, K. et al. Pif1 family helicases suppress genome instability at
G-quadruplex motifs. Nature 497, 458–462 (2013).
33. Doe, C. L., Ahn, J. S., Dixon, J. & Whitby, M. C. Mus81-Eme1 and Rqh1
involvement in processing stalled and collapsed replication forks. J. Biol. Chem.
277, 32753–32759 (2002).
34. Mateos-Gomez, P. A. et al. Mammalian polymerase y promotes alternative
NHEJ and suppresses recombination. Nature 518, 254–257 (2015).
35. Koole, W. et al. A Polymerase Theta-dependent repair pathway suppresses
extensive genomic instability at endogenous G4 DNA sites. Nat. Commun. 5,
3216 (2014).
36. Marcotte, R. et al. Functional genomic landscape of human breast cancer
drivers, vulnerabilities, and resistance. Cell 164, 293–309 (2016).
37. Ward, I. M. et al. 53BP1 is required for class switch recombination. J. Cell Biol.
165, 459–464 (2004).
38. Manis, J. P. et al. 53BP1 links DNA damage-response pathways to
immunoglobulin heavy chain class-switch recombination. Nat. Immunol. 5,
481–487 (2004).
39. Brenner, S. Caenorhabditis elegans. Methods (1974).
40. Stirling, P. C. et al. Mutability and mutational spectrum of chromosome
transmission ﬁdelity genes. Chromosoma 121, 263–275 (2012).
41. Bostock, C. J., Prescott, D. M. & Kirkpatrick, J. B. An evaluation of the double
thymidine block for synchronizing mammalian cells at the G1-S border. Exp.
Cell Res. 68, 163–168 (1971).
42. Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes
homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13,
2633–2638 (1999).
43. Collins, A. R. The comet assay for DNA damage and repair. Mol. Biotechnol.
26, 249–261 (2004).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14432 ARTICLE
NATURE COMMUNICATIONS | 8:14432 |DOI: 10.1038/ncomms14432 | www.nature.com/naturecommunications 17
44. Rosche, W. A. & Foster, P. L. Determining mutation rates in bacterial
populations. Methods 20, 4–17 (2000).
45. Stirling, P. C. et al. R-loop-mediated genome instability in mRNA cleavage and
polyadenylation mutants. Genes Dev. 26, 163–175 (2012).
46. Schmidt, D. et al. ChIP-seq: using high-throughput sequencing to discover
protein–DNA interactions. Methods 48, 240–248 (2009).
47. Chambers, V. S. et al. High-throughput sequencing of DNA G-quadruplex
structures in the human genome. Nat. Biotechnol. 33, 877–881 (2015).
48. Tan, B. C. et al. Epigeneitc silencing of ribosomal RNA genes by Mybbp1a.
J. Biomed. Sci. 19, 57 (2012).
49. Iman, R. L. A power study of a rank transform for the two-way classiﬁcation
model when interaction may be present. Can. J. Stat. 2, 227–239 (1974).
50. Friedman, J. H. SMART User’s Guide (1984).
51. Kalbﬂeisch, J. D. & Prentice, R. L. The Statistical Analysis of Failure Time Data
(John Wiley & Sons, 2011).
52. TARONE, R. E. Tests for trend in life table analysis. Biometrika 62, 679–690
(1975).
53. Kuhn, M., Wing, J., Weston, S., Williams, A. & Keefer, C. The R Core Team
(Benesty, 2015).
54. Benjamini, Y. & Hochberg, Y. On the adaptive control of the false discovery
rate in multiple testing with independent statistics. J. Educ. Behav. Stat. 25,
60–83 (2000).
55. Bates, D., Maechler, M., Bolker, B. & Walker, S. lme4: Linear Mixed-Effects
Models Using Eigen and S4. R Package Version (2014).
56. Hothorn, T., Bretz, F. & Westfall, P. Simultaneous inference in general
parametric models. Biom. J. 50, 346–363 (2008).
Acknowledgements
We greatly appreciate Dr Jos Jonkers’ lab for generously distributing mouse mammary
tumour BRCA2 knockout cells (K14-Cre; Brca2F11/F11; p53F2-10/F2-10) and control mouse
mammary tumour BRCA2 proﬁcient cells (K14-Cre; Brca2wt/wt; p53F2-10/F2-10);
Toshiyasu Taniguchi’s lab for sharing C4-2 and PEO1 cells; Benjamin G. Neel’s lab for
sharing the 50 breast cancer cell lines; Ross D. Hannan, Geraldine Aubert, and Tehmina
Masud for helpful suggestions to this paper.
This work was supported by the Canadian Breast Cancer Foundation BC/Yukon,
BC Cancer Foundation, Stand Up to Cancer Canada (SU2C-AACR-DT-18-15),
TFRI Grant 1021, CCSRI Grant 701584, CIHR Grant MOP-126119, Canada Foundation
for Innovation and Cancer Research UK. Grant Brown lab is supported by CCSRI Impact
Grant 702310 (to G.W.B.) and Ontario Government Scholarship (to B.H.). S.A. is
supported by a Canada Research Chair in Molecular Oncology. The Balasubramanian lab
is supported by a programme grant (C14303/A17197) and core funding (C14303/
A17197) from Cancer Research UK.
Author contributions
H.X., S.A., S.B., P.H., P.C.S., D.C., T.W.M., C.C., M.B.B., J.B. G.W.B. designed
the experiments. H.X., M.D.A., V.M., B.H., N.J.O., N.D.S., J.S., V.W., J.G., P.C.S.,
A.H.C.T., F.K., D.D. Le, D.Y., F.B.Y., J.B., A.Z., K.T., J.S., S.L., T.O., T.A., D.S., J.W.
performed the experiments. S.M., D. Lai, and D.S.C. analysed the data. J.X. created
BRCA2 / HCT116 cell line. H.X., M.D.A., V.M., N.J.O. S.S. and S.A. wrote
the paper.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: J.S. and S.L. are employees of Senwah Biosciences Ltd.
The other authors have no conﬂicts of interest to declare.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Xu, H. et al. CX-5461 is a DNA G-quadruplex stabilizer
with selective lethality in BRCA1/2 deﬁcient tumours. Nat. Commun. 8, 14432
doi: 10.1038/ncomms14432 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14432
18 NATURE COMMUNICATIONS | 8:14432 |DOI: 10.1038/ncomms14432 | www.nature.com/naturecommunications
